Cytoplasmic dynein-1 is a molecular motor that drives nearly all minus-end-directed microtubule-based transport in human cells, performing functions ranging from retrograde axonal transport to mitotic spindle assembly 1,2 . Activated dynein complexes consist of one or two dynein dimers, the dynactin complex, and an "activating adaptor", with maximal velocity seen with two dimers present ( Fig. 1a ) 3-6 . Little is known about how this massive ~4MDa complex is assembled. Using purified recombinant human proteins, we uncovered a novel role for the dynein-binding protein, Lis1, in the formation of fully activated dynein complexes containing two dynein dimers. Lis1 is required for maximal velocity of complexes activated by proteins representing three different families of activating adaptors: BicD2, Hook3, and Ninl. Once activated dynein complexes have formed, they do not require the presence of Lis1 for sustained maximal velocity. Using cryo-electron microscopy we show that human Lis1 binds to dynein at two sites on dynein's motor domain, similar to yeast dynein 7 . We propose that the ability of Lis1 to bind at these sites may function in multiple stages of assembling the motile human dynein/ dynactin/ activating adaptor complex.
Cytoplasmic dynein-1 (dynein) is responsible for the long-distance transport of nearly all cargos that move towards the minus ends of microtubules, including organelles, membrane vesicles, and protein and RNA complexes in many eukaryotic cells. Dynein also has roles in cell division, and viruses hijack dynein for their transport 2 . Mutations in components of the dynein machinery cause neurodevelopmental and neurodegenerative diseases 8 . Activated human dynein is a large ~4MDa multi-subunit complex composed of one or two dynein dimers (each dynein dimer contains two motor subunits and two copies each of five additional subunits), the dynactin complex (composed of 23 polypeptides) and one of several classes of dimeric, coiled-coilcontaining activating adaptors (Fig. 1a) [2] [3] [4] [5] [6] 9 . The dynein motor-containing subunit, or heavy chain, is an ATPase containing six AAA+ domains and a microtubule-binding domain that emerges from a long coiled-coil "stalk" (Fig. 1b) .
Mammalian dynein (but not yeast dynein 10 ) is largely immotile in the absence of dynactin and an activating adaptor 3, 4, 11 . Activating adaptors also link dynein/ dynactin either directly or indirectly to its cargos 2, 9 . Nearly a dozen activating adaptors have been described; they share little sequence identity, but all contain a long stretch of coiled-coil that spans the ~40 nm length of dynactin 2, 9 . All activated dynein complexes that have been investigated structurally can bind two dynein dimers 5, 6 , referred to as "dynein A" and "dynein B" (Fig. 1a ).
Mammalian dynein in the absence of these other components adopts a conformation known as "Phi" 12, 13 . Phi dynein is autoinhibited and cannot interact with microtubules productively 12 . The current model for dynein activation proposes that Phi dynein must first adopt an "Open" conformation and then ultimately a "Parallel" conformation that is observed when it is bound to dynactin and an activating adaptor ( Fig. 1a ) 5, 6 . Little is known about how dynein switches between the autoinhibited Phi conformation and the Open and Parallel conformations that lead to the assembly of the motile activated dynein/ dynactin complex. Genetic studies in model organisms place the dynein-binding protein, Lis1, in the dynein pathway [14] [15] [16] . Lis1 is required for many dynein functions ranging from organelle trafficking (for example [17] [18] [19] [20] to nuclear migration/positioning (for example 15, [21] [22] [23] ) to RNA localization (for example 24 ). The LIS1 gene is mutated in the neurodevelopmental disease type-1 lissencephaly 25 , and was first directly linked to dynein through genetic studies in the filamentous fungus Aspergillus nidulans 15 . Lis1 is a dimer of propellers 26, 27 and yeast Lis1 binds dynein at two distinct sites in the dynein motor domain 7, 28, 29 . One site is located on dynein's ATPase ring near AAA3 and AAA4 ("site ring ") and the other is located on dynein's stalk ("site stalk "), which leads to its microtubule-binding domain 7, 28, 29 (Fig. 1b.) . In yeast, binding of Lis1 to dynein at site ring causes tight microtubule binding and decreased velocity 7, 29 , whereas binding at both sites leads to weak microtubule binding and increased velocity 7 . Lis1 also increases the binding of mammalian dynein to microtubules 30, 31 and increases the velocity of mammalian dynein/ dynactin complexes containing the BicD2 activating adaptor 32, 33 . How Lis1 exerts these effects on mammalian dynein is unknown. It is also unknown if Lis1 has the same effects on dynein/ dynactin bound to other activating adaptors. Dynein is autoinihibited in the Phi conformation, opens and then adopts a parallel conformation that is seen in the activated dynein complex, which includes dynactin and an activating adaptor. Maximally activated dynein contains two dynein dimers (dynein A and B, far right) b. Schematic of the dynein motor domain with AAA+ ATPase domains colored in rainbow, highlighting the two Lis1 binding sites in yeast dynein, "site ring" at AAA3/4 and "site stalk " on dynein's stalk, which leads to dynein's microtubule binding domain (MTBD). Lis1 is shown in orange to the right c. Schematic of the activating adaptor constructs used in this study. d. Binding density (mean ± s.e.m. dynein) of dynein alone on microtubules in the absence (white circles) or presence (black circles) of 300 nM Lis1. Data was normalized to a density of 1.0 in the absence of Lis1. Statistical analysis was performed using a two-tailed unpaired t test; ****, p<0.0001; n = 12 replicates for each condition. e. Binding density (mean ± s.e.m) of dynein/ dynactin/ activating adaptor complexes on microtubules in the absence (white circles) or presence (black circles) of 300 nM Lis1. The activating adaptors used are indicated. Data was normalized to a density of 1.0 in the absence of Lis1. Statistical analysis was performed using a two-tailed unpaired t test; ****, p<0.0001; n = 12 replicates for each condition. f. Velocity of dynein/ dynactin/ activating adaptor complexes in the absence (white circles) or presence (black circles) of 300 nM Lis1. The median and interquartile range are shown and the activating adaptors used are indicated. Statistical analysis was performed using a two-tailed Mann-Whitney test; ****, p<0.0001; ns, p=0.3498; n (individual single molecule events) = 506 (BicD2-S no Lis1), 569 (BicD2-S with Lis1), 496 (BicD2-L no Lis1), 505 (BicD2-L with Lis1), 454 (Hook3 no Lis1), 471 (Hook3 with Lis1), 490 (Ninl no Lis1), 582 (Ninl with Lis1). g. Percent processive runs (mean ± s.e.m.) of dynein/ dynactin/ Hook3 complexes in a higher salt buffer (60 mM KOAc versus 30 mM KOAc in our standard motility buffer) in the absence (white circles) or presence (black circles) of 300 nM Lis1. Statistical analysis was performed using a one-way ANOVA and Tukey's multiple comparisons test; ****, p<0.0001; n = 3 replicates per condition. h. Schematic of the peroxisome relocation assay. i. Peroxisome velocity in human U2OS cells with scrambled or Lis1 siRNA knockdown. The median and interquartile range are shown. Statistical analysis was performed using a two-tailed unpaired t test; ***, p=0.0002; n (average peroxisome velocity per cell) = 30 per condition. More than 7 events were measured per cell.
To determine how Lis1 regulates activated human dynein complexes we purified human dynein 3 and Lis1 from insect cells, dynactin from human HEK-293T cells 34 , and the human activating adaptors BicD2, Hook3, and Ninl from E. coli ( Supplementary Fig.  1a ). Since some activating adaptors are known to be autoinhibited 35 , we chose to use well-characterized carboxy-terminal truncations of BicD2, Hook3 and Ninl 3, 4, 34 (Fig. 1c ). For BicD2 we made both short (BicD2-S) and long (BicD2-L) forms, which have been shown to activate dynein in vitro 3, 4 and in cells 18, 36 , respectively.
We first determined the effects of Lis1 on the microtubule binding properties of dynein alone and dynein/ dynactin bound to different activating adaptors using a singlemolecule assay 7 . Lis1 increased the microtubule binding density of dynein alone (Fig.  1d ), consistent with studies of yeast 7, 29 and mammalian 30, 31 dynein. Lis1 also increased the microtubule binding density of dynein/ dynactin complexes bound by the activating adaptors BicD2-S, BicD2-L, Hook3, and Ninl ( Fig. 1e ).
Next, we determined the effect of Lis1 on the velocity of activated dynein complexes. In agreement with some previous studies 32, 33 , we found that Lis1 increased the velocity of dynein/ dynactin / BicD2-S complexes ( Fig. 1f ). We also found that Lis1 increased the velocity of dynein/ dynactin activated by BicD2-L and Ninl, but not Hook3 in our standard motility assay buffer ( Fig. 1f ). However, when we raised the salt concentration in our assay buffer we found that Lis1 increased the percentage of dynein/ dynactin/ Hook3 microtubule binding events that are processive ( Fig. 1g ) and also increased the velocity of these processive runs ( Supplementary Fig. 1b ). We interpret this difference in sensitivity to the ionic strength of our assay conditions as an indication that Hook3 may have a higher affinity for dynein B compared to BicD2 and Ninl. Overall this data shows that Lis1 increases both microtubule binding and motility of dynein/ dynactin complexes bound by activating adaptors from three different families.
We next asked if Lis1 had a similar effect on activated dynein velocity in cells using a well-established peroxisome relocation assay ( Fig. 1h) 36, 37 . We co-transfected human U2OS cells with two constructs: 1) the rapamycin binding protein FRB fused to BicD2-S and 2) the rapamycin binding protein FKBP fused to both mEmerald and the peroxisome targeting protein Pex3 (Fig. 1h ). In U2OS cells peroxisomes rarely move, but upon the addition of rapalog, which causes FRB and FKBP to interact we observed many processive runs. This is an indication that BicD2-S recruits and activates dynein/ dynactin (Supplementary videos 1-4) 37 . We quantified the velocity of these runs in cells with or without Lis1 knockdown by siRNA ( Supplementary Fig. 1c ) and observed a significant decrease in peroxisome velocity in Lis1 knockdown cells ( Fig. 1i ). These results suggest that in a cellular environment the presence of Lis1 also increases the velocity of activated dynein complexes.
We next sought to determine where Lis1 binds the human dynein motor. Experiments with the yeast homologs of dynein and Lis1 have shown that Lis1 binds dynein at two sites in the dynein motor domain (on the ring at AAA3/4 and on the stalk; Fig. 1b ) 7, 28, 29 , although previous studies with mammalian proteins reported interactions with other regions of dynein 38, 39 . Here we used cryo-electron microscopy (cryo-EM) to identify the Lis1 binding sites on human dynein. We purified monomeric human dynein motor domains and mixed them with dimeric human Lis1 in the presence of ATPvanadate. Although the strong preferred orientation adopted by the sample prevented us from obtaining a three-dimensional reconstruction, we generated two-dimensional (2D) class averages of the dynein/ Lis1 complex; these averages showed high-resolution features in both dynein and Lis1 ( Fig. 2a ). To determine whether the binding sites for Lis1 are similar in both human and yeast dynein, we compared our experimental class averages with calculated 2D projections of a model of human dynein bound to Lis1. To make this model we combined the structure of human dynein-2 bound to ATP-vanadate (PDB: 4RH7 40 ) with a homology model of human Lis1 bound to dynein at the two binding sites observed with the yeast proteins (PDB: 5VLJ 7 ) ( Fig. 2b) . To highlight the densities corresponding to Lis1, we also calculated 2D projections of human dynein-2 alone in the same orientations as our experimental data (Fig. 2c ). The correspondence between our data and the model with two Lis1s bound ( Fig. 2a,b ) suggests that the yeast and human Lis1 binding sites are in similar regions of the dynein motor domain on the ring at AAA3/4 and on the stalk, although in the absence of a high-resolution 3D reconstruction we cannot map the exact locations on either dynein or Lis1.
Mutation of 5 amino acids on the dynein binding face of the yeast Lis1 -propeller disrupts the interaction between the dynein motor domain and Lis1 7,28 . We made the equivalent mutations in human Lis1 ("Lis1-5A"; Fig. 2d ). We first asked if Lis1-5A could enhance the velocity of activated dynein complexes. We focused on dynein/ dynactin complexes activated by BicD2-S for these experiments, as Lis1 had the greatest effect on these complexes ( Fig. 1 ). We found that 300 nM Lis1-5A could still enhance the velocity of dynein/ dynactin/ BicD2-S complexes. We hypothesized that the mutations in Lis1-5A might not completely disrupt the dynein interaction. Thus, we lowered the concentration of Lis1 and Lis1-5A to 24 nM and found that under these conditions Lis1-5A increased velocity significantly less than wild type Lis1 ( Fig. 2e ). Next, we asked if the Lis1-5A mutant could increase the percentage of processive runs for dynein/ dynactin/ Hook3 complexes. We observed significantly fewer processive runs of dynein/ dynactin/ Hook3 complexes in the presence of Lis1-5A compared to wild type Lis1 ( Fig.  2f ) and the velocity of these complexes was no longer increased ( Supplementary Fig.  2a ). A high-resolution structure of the human dynein/ Lis1 complex will be required to map the Lis1/ dynein binding sites in detail.
Since Lis1 is a dimer, we wondered whether Lis1's role in forming activated complexes required dimerization. To test this, we purified monomeric human Lis1, which lacks its amino-terminal dimerization domain. Our data indicate that dimerization is not required for Lis1 to increase dynein velocity: we found that monomeric Lis1 could still increase complex formation at the same molar ratio of dynein to Lis1 -propellers ( Fig. 2g ).
As activated dynein complexes containing two dynein dimers are faster than those containing a single one 5 , we hypothesized that Lis1 may maximally activate dynein by promoting the recruitment of a second dynein dimer to the complex. First, we sought to determine if Lis1 enhances the formation of dynein/ dynactin complexes in vitro. We measured the formation of activated dynein complexes by mixing dynein and dynactin with a molar excess of each activating adaptor conjugated to magnetic beads via their carboxy-terminal HaloTags. We then quantified the percentage of dynein depleted from the supernatant after the beads were pelleted with a magnet (Fig. 3a) .
The presence of Lis1 increased the percentage of dynein depleted by each activating adaptor ( Fig. 3b ) and dynactin was required for this effect ( Supplementary Fig. 3a,b ).
To directly test if Lis1 promotes the recruitment of a second dynein dimer we performed a two-color single-molecule assay where we mixed equimolar amounts of dynein labeled (on the heavy chain subunit) with either TMR or Alexa647. In this assay, if all moving activated dynein complexes contain two dynein dimers, 50% of motile events will show co-localized dynein-TMR and dynein-Alexa647 ( Fig. 3c ). We found that the presence of Lis1 significantly increased the number of moving two-color activated dynein/ dynactin/ BicD2-S complexes (Fig. 3d,e ). From these experiments, we conclude that Lis1 promotes the recruitment of a second dynein dimer to form maximally activated dynein complexes. We wondered if Lis1 must remain bound to moving activated dynein complexes to sustain fast velocity. To address this, we sought to determine if TMR-labeled Lis1 comigrated with moving dynein/ dynactin/ BicD2-S complexes tagged with Alexa647 (on the dynein heavy chain subunit). For most of our earlier experiments we used 300 nM Lis1, a concentration that is too high to visualize single Lis1 molecules. Therefore, we lowered the Lis1 concentration to 50 nM, a concentration where Lis1 still increased the velocity of dynein/ dynactin/ BicD2-S complexes (Fig. 4a ). When we performed singlemolecule motility assays with TMR-Lis1 and Alexa647-dynein/ dynactin/ BicD2-S complexes we found that only 16.8 ± 1.9% of dynein runs comigrated with Lis1 and those runs that did comigrate moved significantly slower than those with no detectable Lis1 (Fig. 4b,c ). On a few occasions we were able to capture the disappearance of the TMR-Lis1 signal coincided with an increase in speed of activated dynein/ dynactin/ BicD2-S runs (Fig. 4d ). When we performed the same experiment with the Lis1-5A mutant, we found that it increased velocity significantly less than wild type Lis1 ( Supplementary Fig. 4a ). However, we observed no colocalization of Lis1-5A with dynein ( Supplementary Fig. 4b ). These results suggest that the presence of Lis1 is not required for sustained maximal velocity of activated dynein complexes. One of the dynein protomers in the Phi conformation (PDB: 5NVU) was aligned to the structure of yeast dynein (AAA3-Walker B) bound to Lis1 in the presence of ATP-vanadate (PDB: 5VLJ). The inset, which shows the cryo-EM map for the yeast structure with Lis1 docked at its AAA3/4 binding site (site ring ), highlights the steric incompatibility between the Phi conformation and binding of Lis1 at AAA3/4. b. Determination of the binding affinity of Lis1 for wild type dynein (blue, K d = 144 nM ± 25) and Open dynein (green, K d = 80 nM ± 8.1). c. Percent (mean ± s.e.m.) depletion of WT dynein (blue) and Open dynein (green) by BicD2-S conjugated to beads in the absence (white circles) or presence (black circles) of 150 nM Lis1. Data with WT dynein in the presence and absence of Lis1 is also presented in Fig. 3b . Statistical analysis was performed using a two-tailed unpaired t test with Bonferroni corrected significance levels for two comparisons; ***, p=0.0003; **, p=0.0008; *, p=0.0118; ns, p=0.4857; n = 3 replicates per condition. d. Velocity of dynein/ dynactin/ BicD2-S complexes with wild type dynein (blue) and Open dynein (green) in the absence (white circles) or presence (black circles) of 300 nM Lis1. The median and interquartile range are shown. Data with WT dynein with and without Lis1 was also presented in Fig. 1f . Statistical analysis was performed using a two-tailed unpaired t test with Bonferroni corrected significance levels for two comparisons; ***, p<0.0001; *, p=0.0241; n (individual single molecule events) = 506 (WT dynein no Lis1), 569 (WT dynein with Lis1), 517 (Open dynein no Lis1), 507 (Open dynein with Lis1). e. Percent two-color colocalized runs (mean ± s.e.m.) with activated dynein complexes with Open dynein in the absence (white circles) or presence (black circles) of 300 nM Lis1. Statistical analysis was performed using a chi-squared test; ***, p=0.0010; n = 395 (no Lis1), 435 (with Lis1). f. Model for the roles of Lis1 in forming activated dynein complexes. See text for details.
Together our data indicate that Lis1 plays a role in the formation of maximally activated dynein complexes. We next explored at which step(s) of the dynein assembly pathway Lis1 was acting (Fig. 1a) . Specifically, because the site ring Lis1 binding site on dynein is not accessible in Phi dynein (Fig. 5a ), we wondered if Lis1 could shift the equilibrium of Phi to Open dynein. In agreement with this idea, we found that Lis1 had a higher affinity for a dynein mutant that does not form the Phi conformation (K1610E and R1567E 12 , "Open dynein"; Fig. 5b ). Next, we asked if Lis1 influenced dynein/ dynactin/ activating adaptor complex formation or velocity when the dynein used was the Open dynein mutant. We first examined Open dynein complexes in the absence of Lis1 and found that these dynein/ dynactin/ BicD2-S complexes were more likely to form and moved faster compared to complexes containing wild type dynein (Fig. 5c,d) . We then asked if Lis1 affected activated complexes containing Open dynein. We found that Lis1 further increased complex formation and velocity of open dynein/dynactin/BicD2-S. Lis1 also increased the percentage of two dynein complexes when Open dynein was used ( Fig. 5e ).
Together our work suggests that Lis1 promotes the formation of activated dynein complexes reconstituted with purified human components. Experiments in human cells 18 , Drosophila embryos 24 , and Xenopus extracts 41 have also shown that Lis1 is required for the interaction of dynein and dynactin with either its cargos or dynactin. Based on our data, our current model of dynein activation by Lis1 consists of three elements (Fig. 5f ).
First, Lis1 may promote the Open dynein conformation. We hypothesize that this could occur by Lis1 shifting the equilibrium between Phi and Open dynein by binding to dynein at site ring (Fig. 5f, step 1) . We propose this based on our data showing that human Lis1 binds dynein at site ring (which is inaccessible in Phi dynein, Fig. 5a ), and our data showing that Lis1 has a higher affinity for dynein that cannot form the Phi particle. An assay that can report on both the Phi and Open conformation will be required to directly test this.
Second, Lis1 promotes or stabilizes the Parallel dynein conformation. We hypothesize that Lis1 binding to Open dynein favors a dynein conformation that leads to the assembly of the fully activated dynein complex ( Fig. 5f , steps 2-4). Our data showing that the Open dynein mutant is further activated by Lis1 supports this idea. While we cannot rule out that some percentage of Open dynein molecules still adopt a partially autoinhibited conformation (that could be relieved by Lis1 as proposed above), we think this is unlikely given previous EM studies showing that the Open dynein mutant does not form Phi particles 12 . Our data also provide mechanistic insight for how Lis1 promotes complex formation. Our cryo-EM data shows that human Lis1, like yeast Lis1 7 , interacts with dynein at two sites on its motor domain. A high-resolution structure of human dynein bound to Lis1 and mutagenesis of both sites on dynein will be required to determine the role of each binding site in complex formation. However, because the Lis1-5A mutant is defective in supporting complex formation, and in yeast Lis1-5A mutants have a similar phenotype to site ring mutants 7,28 , we hypothesize that binding at this site will be important for activated complex assembly. Importantly, because we found that monomeric Lis1 still influenced activated complex formation, Lis1 is likely not functioning by cross-linking adjacent dynein dimers (dynein A and B).
Third, Lis1 is not required for sustained dynein velocity. We hypothesize that Lis1 facilitates the formation of dynein/ dynactin/ activator complexes, but dissociates from moving complexes (Fig. 5f, step 5 ). Complex formation may occur at microtubule plus ends as previous in vitro studies showed that Lis1 increases the binding of activated dynein complexes to microtubule plus ends 42 . This component of our model is based on our data showing that most moving dynein complexes do not remain bound to Lis1 and those that do, move slower. This is in agreement with studies in Aspergillus nidulans showing that Lis1 is required for the initiation of endosome motility, but does not colocalize with moving endosomes 43 . We propose that filamentous fungi like A. nidulans, which have Hook-related activating adaptors that are required for dyneinbased motility of endosomes 44, 45 , also use Lis1 to promote activated dynein complex formation. Our model may also be conserved in yeast. While S. cerevisiae dynein is processive in vitro in the absence of dynactin or an activating adaptor 10 , Lis1 is required for dynein/ dynactin localization to its site of activation (the cortex) in vivo 21, 46 . In yeast both dynein 47 and Num1 48 , a candidate activating adaptor 49, 50 localize to the cortex, while a stable pool of Lis1 is not observed there 21, 51 .
Finally, we have shown that proteins representing three distinct families of activating adaptors, BicD2, Hook3, and Ninl, all require Lis1 for full activation. This raises the possibility that many activated dynein complexes in cells may consist of two dynein dimers, dynactin, and an activating adaptor. We hypothesize that related activating adaptors or candidate activating adaptors will also require Lis1 to maximally activate dynein/ dynactin. In humans there are three additional BicD family members (BicD1, BicDL1, and BicDL2), two additional Hook family members (Hook1 and Hook2), and additional proteins that share a similar domain structure in their dynein/ dynactin binding regions to the Hook proteins (CCDC88A, CCDC88B, and CCDC88C) or Ninl (Nin, Rab11-FIP3, CRACR2a, Rab 44, and Rab 45) 2, 9, 52 . Thus, we predict that Lis1 will play a role in the cell biological processes that all of these activating adaptors or candidate activating adaptors facilitate. 
METHODS

Cloning, plasmid construction, and mutagenesis
The pDyn1 plasmid (the pACEBac1 expression vector containing insect cell codon optimized dynein heavy chain (DYNC1H1) fused to a His-ZZ-TEV tag on the aminoterminus and a carboxy-terminal SNAPf tag (New England Biolabs)) and the pDyn2 plasmid (the pIDC expression vector with codon optimized DYNC1I2, DYNC1LI2, DYNLT1, DYNLL1, and DYNLRB1) were recombined in vitro with a Cre recombinase (New England Biolabs) to generate the pDyn3 plasmid. The presence of all six dynein chains was verified by PCR. pDyn1, pDyn2 and the pFastBac plasmid with codonoptimized human full-length Lis1 (PAFAH1B1) fused to an amino-terminal His-ZZ-TEV tag and pFastBac containing human dynein monomer (amino acids 1320-4646 of DYNC1H1) were gifts from Andrew Carter (LMB-MRC, Cambridge, UK). BicD2 constructs were amplified from a human cDNA library generated from RPE1 cells and the other activating adaptor constructs were obtained as described previously 34 . Activating adaptors were fused to a ZZ-TEV-HaloTag (Promega) on the amino-terminus and inserted into a pET28a expression vector. All additional tags were added via Gibson assembly and all mutations and truncations were made via site-directed mutagenesis (Agilent). For rapalog induced motility in cells, HaloTag-BicD2-S was cloned into the pcDNA5 backbone with a carboxy-terminal V5 epitope tag fused to FRB. The peroxisome tag PEX3 was cloned into pcDNA5 with a carboxy-terminal mEmerald fluorescent protein and FKBP.
Protein expression and purification
Human full-length dynein, human dynein monomer, and human Lis1 constructs were expressed in Sf9 cells as described previously 3, 32 . Briefly, the pDyn3 plasmid containing the human dynein genes or the pFastBac plasmid containing full-length Lis1 or dynein monomer was transformed into DH10EmBacY chemically competent cells with heat shock at 42°C for 15 seconds followed by incubation at 37°C for 5 hours in S.O.C media (Thermofisher scientific). The cells were then plated on LB-agar plates containing kanamycin (50 μg/ml), gentamicin (7 μg/ml), tetracyclin (10 μg/ml), BluoGal (100 μg/ml) and IPTG (40 μg/ml) and positive clones were identified by a blue/white color screen after 48 hours. For full-length human dynein constructs, white colonies were additionally tested for the presence of all six dynein genes using PCR. These colonies were then grown overnight in LB medium containing kanamycin (50 μg/ml), gentamicin (7 μg/ml) and tetracyclin (10 μg/ml) at 37°C. Bacmid DNA was extracted from overnight cultures using an isopropanol precipitation method as described previously 12 . 2mL of Sf9 cells at 0.5x10 6 cells/mL were transfected with 2µg of fresh bacmid DNA and FuGene HD transfection reagent (Promega) at a 3:1 transfection reagent to DNA ratio according to the manufacturer's instructions. After three days, the supernatant containing the "V0" virus was harvested by centrifugation at 200 x g for 5 minutes at 4°C. To generate "V1", 1 mL of the V0 virus was used to transfect 50mL of Sf9 cells at 1x10 6 cells/mL. After three days, the supernatant containing the V1 virus was harvested by centrifugation at 200 x g for 5 minutes at 4°C and stored in the dark at 4°C until use. For protein expression, 4 mL of the V1 virus were used to transfect 400 mL of Sf9 cells at 1x10 6 cells/mL. After three days, the cells were harvested by centrifugation at 3000 x g for 10 minutes at 4°C. The pellet was resuspended in 10 mL of ice-cold PBS and pelleted again. The pellet was flash frozen in liquid nitrogen and stored at -80°C.
Protein purification steps were done at 4°C unless otherwise indicated. Fulllength dynein and dynein monomer were purified from frozen Sf9 pellets transfected with the V1 virus as described previously 3 . Frozen cell pellets from a 400 mL culture were resuspended in 40 mL of Dynein-lysis buffer (50 mM HEPES [pH 7.4], 100 mM sodium chloride, 1 mM DTT, 0.1 mM Mg-ATP, 0.5 mM Pefabloc, 10% (v/v) glycerol) supplemented with 1 cOmplete EDTA-free protease inhibitor cocktail tablet (Roche) per 50 mL and lysed using a Dounce homogenizer (10 strokes with a loose plunger and 15 strokes with a tight plunger). The lysate was clarified by centrifuging at 183,960 x g for 88 min in Type 70 Ti rotor (Beckman). The clarified supernatant was incubated with 4 mL of IgG Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences) for 3-4 hours on a roller. The beads were transferred to a gravity flow column, washed with 200 mL of Dynein-lysis buffer and 300 mL of TEV buffer (50 mM Tris-HCl [pH 8.0], 250 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 0.1 mM Mg-ATP, 10% (v/v) glycerol). For fluorescent labeling of carboxy-terminal SNAPf tag, dynein-coated beads were labeled with 5 µM SNAP-Cell-TMR (New England Biolabs) in the column for 10 min at room temperature and unbound dye was removed with a 300 mL wash with TEV buffer at 4°C. The beads were then resuspended and incubated in 15 mL of TEV buffer supplemented with 0.5 mM Pefabloc and 0.2 mg/mL TEV protease (purified in the Reck-Peterson lab) overnight on a roller. The supernatant containing cleaved proteins was concentrated using a 100K MWCO concentrator (EMD Millipore) to 500 µL and purified via size exclusion chromatography on a TSKgel G4000SWXL column (TOSOH Bioscience) with GF150 buffer (25 mM HEPES [pH7.4] , 150 mM KCl, 1mM MgCl2, 5 mM DTT, 0.1 mM Mg-ATP) at 1 mL/min. The peak fractions were collected, buffer exchanged into a GF150 buffer supplemented with 10% glycerol, concentrated to 0.1-0.5 mg/mL using a 100K MWCO concentrator (EMD Millipore) and flash frozen in liquid nitrogen.
Lis1 constructs were purified from frozen cell pellets from 400 mL culture. Lysis and clarification steps were similar to full-length dynein purification except Lis1-lysis buffer (30 mM HEPES [pH 7.4], 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 300 mM potassium chloride, 1 mM DTT, 0.5 mM Pefabloc, 10% (v/v) glycerol) supplemented with 1 cOmplete EDTA-free protease inhibitor cocktail tablet (Roche) per 50 mL was used. The clarified supernatant was incubated with 0.5 mL of IgG Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences) for 2-3 hours on a roller. The beads were transferred to a gravity flow column, washed with 20 mL of Lis1lysis buffer, 100 mL of modified TEV buffer (10 mM Tris-HCl [pH 8.0], 2 mM magnesium acetate, 150mM potassium acetate, 1 mM EGTA, 1 mM DTT, 10% (v/v) glycerol) supplemented with 100 mM potassium acetate, and 50 mL of modified TEV buffer. For fluorescent labeling of Lis1 constructs with amino-terminal HaloTags, Lis1coated beads were labeled with 200 µM Halo-TMR (Promega) for 2.5 hours at 4°C on a roller and the unbound dye was removed with a 200 mL wash with modified TEV buffer supplemented with 250 mM potassium acetate. Lis1 was cleaved from IgG beads via incubation with 0.2 mg/mL TEV protease overnight on a roller. The cleaved Lis1 was filtered by centrifuging with an Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge and flash frozen in liquid nitrogen.
Dynactin was purified from stable HEK293-T cell lines expressing p62-Halo-3xFlag as described previously 34 . Briefly, frozen pellets collected from 160 x 15cm plates were resuspended in 80 mL of Dynactin-lysis buffer (30 mM HEPES [pH 7.4], 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 10% (v/v) glycerol) supplemented with 0.5 mM Mg-ATP, 0.2% Triton X-100 and 1 cOmplete EDTA-free protease inhibitor cocktail tablet (Roche) per 50 mL and rotated slowly for 15 min. The lysate was clarified by centrifuging at 66,000 x g for 30 min in Type 70 Ti rotor (Beckman). The clarified supernatant was incubated with 1.5 mL of anti-Flag M2 affinity gel (Sigma-Aldrich) overnight on a roller. The beads were transferred to a gravity flow column, washed with 50 mL of wash buffer (Dynactin-lysis buffer supplemented with 0.1 mM Mg-ATP, 0.5 mM Pefabloc and 0.02% Triton X-100), 100 mL of wash buffer supplemented with 250 mM potassium acetate, and again with 100 mL of wash buffer. For fluorescent labeling the HaloTag, dynactin-coated beads were labeled with 5 µM Halo-JF646 (Janelia) in the column for 10 min at room temperature and the unbound dye was washed with 100 mL of wash buffer at 4°C. Dynactin was eluted from beads with 1 mL of elution buffer (wash buffer with 2 mg/mL of 3xFlag peptide). The eluate was collected, filtered by centrifuging with Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge and diluted to 2 mL in Buffer A ( Activating adaptors containing amino-terminal HaloTags were expressed in BL-21[DE3] cells (New England Biolabs) at OD 0.4-0.6 with 0.1 mM IPTG for 16 hr at 18°C. Frozen cell pellets from 2 L culture were resuspended in 60mL of activator-lysis buffer (30 mM HEPES [pH 7.4], 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 0.5 mM Pefabloc, 10% (v/v) glycerol) supplemented with 1 cOmplete EDTA-free protease inhibitor cocktail tablet (Roche) per 50 mL and 1 mg/mL lysozyme. The resuspension was incubated on ice for 30 min and lysed by sonication. The lysate was clarified by centrifuging at 66,000 x g for 30 min in Type 70 Ti rotor (Beckman). The clarified supernatant was incubated with 2 mL of IgG Sepharose 6 Fast Flow beads (GE Healthcare Life Sciences) for 2 hr on a roller. The beads were transferred to a gravity flow column, washed with 100 mL of activator-lysis buffer supplemented with 150 mM potassium acetate and 50mL of cleavage buffer (50 mM Tris-HCl [pH 8.0], 150 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, 1 mM DTT, 0.5 mM Pefabloc, 10% (v/v) glycerol). The beads were then resuspended and incubated in 15 mL of cleavage buffer supplemented with 0.2 mg/mL TEV protease overnight on a roller. The supernatant containing cleaved proteins were concentrated using a 50K MWCO concentrator (EMD Millipore) to 1 mL, filtered by centrifuging with Ultrafree-MC VV filter (EMD Millipore) in a tabletop centrifuge, diluted to 2 mL in Buffer A (30 mM HEPES [pH 7.4], 50 mM potassium acetate, 2 mM magnesium acetate, 1 mM EGTA, then incubated with Lis1 or modified TEV buffer (to buffer match for experiments without Lis1) for 10 min on ice. Dynein alone was used instead of dynein-dynactin-activating adaptor complexes for the experiments with dynein alone. The mixtures of dynein, dynactin, activating adaptor and Lis1 were then flowed into the flow chamber assembled with taxol-stabilized microtubules. The final imaging buffer contained the assay buffer supplemented with 20 µM Taxol, 1 mg/mL casein, 71.5 mM β-mercaptoethanol, an oxygen scavenger system, and 1 mM Mg-ATP. The final concentration of dynein in the flow chamber was 0.5-1 pM for experiments with dynein-dynactin-activating adaptor complexes and 0.3-0.5 pM for dynein alone experiments. The final concentration of Lis1 was between 24 nM -300 nM (as indicated in the main text) for experiments with unlabeled Lis1, and 50 nM for experiments with TMR-labeled Lis1. For single-molecule motility assays, microtubules were imaged first by taking a single-frame snapshot. Dynein and/or the activating adaptor labeled with fluorophores (TMR, Alexa647 or Alexa488) was imaged every 300 msec for 3 min. At the end, microtubules were imaged again by taking a snapshot to assess stage drift. Movies showing significant drift were not analyzed. Each sample was imaged no longer than 15 min. For single-molecule microtubule binding assays, the final imaging mixture containing dynein was incubated for an additional 5 min in the flow chamber at room temperature before imaging. After 5 min incubation, microtubules were imaged first by taking a single-frame snapshot. Dynein and/or activating adaptors labeled with fluorophores (TMR, Alexa647 or Alexa488) were imaged by taking a single-frame snapshot. Each sample was imaged at 4 different fields of view and there were between 5 and 10 microtubules in each field of view. In order to compare the effect of Lis1 on microtubule binding, the samples with and without Lis1 were imaged in two separate flow chambers made on the same coverslip on the same day with the same stock of polymerized tubulin as described previously 7 .
Single-molecule motility assay analysis
Kymographs were generated from motility movies and dynein velocity was calculated from kymographs using ImageJ macros as described 54 . Only runs that were longer than 4 frames (1.2 s) were included in the analysis. Bright aggregates, which were less than 5% of the population, were excluded from the analysis. For two-color colocalization analysis, kymographs from each channel were generated and merged in ImageJ and the number of colocalized runs was determined manually. Data plotting and statistical analyses were performed in Prism8 (GraphPad).
Single-molecule microtubule binding assay analysis
Intensity profiles of dynein or activating adaptor spots from a single-frame snapshot were generated over a 5-pixel wide line drawn perpendicular to the long axis of microtubules in ImageJ. Intensity peaks at least 2-fold higher than the neighboring background intensity were counted as dynein or activating adaptor spots bound to microtubules. Bright aggregates that were 5-fold brighter than the neighboring intensity peaks were not counted. The average binding density was calculated as the total number of dynein or activating adaptor spots divided by the total microtubule length in each snapshot. Normalized binding density was calculated by dividing by the average binding density of dynein or activating adaptor without Lis1 collected on the same fractionated movies were collected in counting mode, with a final calibrated pixel size of 1.16 Å/pixel, a dose rate of ~6 e -/pixel/sec, and a total dose of ~60 e -/Å 2 . Leginon 55 was used for automated data collection and movies were processed on-the-fly using Appion 56 . Movie alignment was performed with MotionCor2 57 defocus estimations were performed with CTFFIND4 58 , and particles were picked using DoG Picker 59 403,439 particles were extracted from 2,422 aligned, dose weighted micrographs in Relion-3 60 with a box size of 288 x 288 pixels and binned by 2 for a final pixel size of 2.32 Å/pixel. The extracted particles were imported into cryoSPARC 2.4.2 for all subsequent analysis 61 . To generate the 2D-class averages shown in figure 2, two rounds of 2D classification were performed. In the first round, 2D classes containing clear density corresponding to the dynein ATPase ring and Lis1 (comprising 71,436 particles) were selected. In the second round, three classes, containing 22,621 total particles were selected for presentation in figure 2 (7,712 particles in the class on the left, 8,943 particles in the class in the middle, 6,506 particles in the class on the right).
To generate a model of human dynein bound to Lis1, we aligned human dynein-2 bound to ATP-vanadate (PDB: 4RH7 40 ) with yeast dynein (AAA3-Walker B) in ATPvanadate and Lis1 (PDB: 5VLJ 7 ) using the part of the sequence that encompasses the two Lis1 binding sites in yeast dynein, from AAA3 until after the binding site for the second Lis1 in the stalk. We then deleted the dynein chain of 5VLJ and combined the remaining two copies of Lis1 with 4RH7. To highlight the densities corresponding to Lis1, we also generated 2D projections of human dynein-2 alone (PDB: 4RH7) in the same orientations as our experimental data.
Peroxisome recruitment assay
Human U2OS cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 1% penicillin/streptomycin. One day before transfection the cells were plated on 35 mm fluorodishes (World Precision Instruments) coated with 100 µg/mL poly-D-lysine (Sigma Aldrich) and 4 µg/mL mouse laminin (Thermo Fisher Scientific). Cells were transfected with 120 ng PEX3-mEMerald-FKBP and BicD2NS-V5-FRB constructs per well as well as 20 pmol of either ON-TARGETplus Non-targeting siRNA #1 (Dharmacon) or SMARTpool: ON-TARGETplus PAFAH1B1 siRNA (Dharmacon) using Lipofectamine 2000 (Thermo Fisher Scientific).
Cells were labelled with Halo-JF549 (Janelia) and imaged after 48 hours using a 100x Apo TIRF NA 1.49 objective on a Nikon Ti2 microscope with a Yokogawa-X1 spinning disk confocal system, MLC400B laser engine (Agilent), Prime 95B backthinned sCMOS camera (Teledyne Photometrics), piezo Z-stage (Mad City Labs) and stage top environmental chamber (Tokai Hit). Cells were screened for the presence of JF549 signal with the 560 laser line and then mEmerald was imaged at 2 frames per second, 100 ms exposure with the 488 laser line. Dimerization of FKBP-FRB was induced with 1 µM rapalog (Takara Bio). Images were analyzed in ImageJ. Kymographs were generated from 6-10 peroxisomes that moved directionally for >3 frames in each cell and velocity was calculated from kymographs using ImageJ macros as described 54 . Data plotting and statistical analyses were performed in Prism7 (GraphPad). 
